YaoGeJu

Company directoryChina company filings

Wuhan Hai Te Biopharmaceutical Co., Ltd. romanized

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference 9f75eb49b0

Complete CDE snapshot
2026/11/13 06:42
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.

Drug filings

26 acceptance records as first applicant, grouped into 21 source drug names. Source data as of 2026/11/13 06:42.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

注射用埃普奈明 · No verified English name 1 records · Latest accepted 2026/07/23

New drug · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CXSL2600766New drug2026/07/23Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗
Bumetanide Injection 2 records · Latest accepted 2026/06/05

Supplement · 1Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2601065Supplement2026/06/05Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗
CYHS2403001Generic2024/09/11Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗
复方莪术油栓 · No verified English name 1 records · Latest accepted 2025/05/08

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2500928Supplement2025/05/08Wuhan Hai Te Biopharmaceutical Co., Ltd. romanized; Hubei Si Huan Pharmaceutical Co., Ltd. romanizedCDE ↗
替硝唑栓 · No verified English name 2 records · Latest accepted 2025/05/07

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2500918Supplement2025/05/07Wuhan Hai Te Biopharmaceutical Co., Ltd. romanized; Hubei Si Huan Pharmaceutical Co., Ltd. romanizedCDE ↗
CYHB2500917Supplement2025/05/07Wuhan Hai Te Biopharmaceutical Co., Ltd. romanized; Hubei Si Huan Pharmaceutical Co., Ltd. romanizedCDE ↗
硝酸咪康唑栓 · No verified English name 1 records · Latest accepted 2025/05/07

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2500920Supplement2025/05/07Wuhan Hai Te Biopharmaceutical Co., Ltd. romanized; Hubei Si Huan Pharmaceutical Co., Ltd. romanizedCDE ↗
联苯苄唑栓 · No verified English name 1 records · Latest accepted 2025/05/07

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2500921Supplement2025/05/07Wuhan Hai Te Biopharmaceutical Co., Ltd. romanized; Hubei Si Huan Pharmaceutical Co., Ltd. romanizedCDE ↗
Policresulen Vaginal Suppositories 1 records · Latest accepted 2025/05/07

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2500922Supplement2025/05/07Wuhan Hai Te Biopharmaceutical Co., Ltd. romanized; Hubei Si Huan Pharmaceutical Co., Ltd. romanizedCDE ↗
Isavuconazonium Sulfate for Injection 1 records · Latest accepted 2024/07/27

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2402379Generic2024/07/27Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗
HT006.2.2滴眼液 · No verified English name 4 records · Latest accepted 2023/07/13

New drug · 4

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CXSL2300475New drug2023/07/13Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗
CXSL2300474New drug2023/07/13Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗
CXSL2300473New drug2023/07/13Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗
CXSL2300472New drug2023/07/13Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗
Esomeprazole Sodium for Injection 1 records · Latest accepted 2023/05/30

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2301460Generic2023/05/30Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗
Pentoxifylline Injection 1 records · Latest accepted 2023/04/10

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2301000Generic2023/04/10Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗
Trimetazidine Dihydrochloride Tablets 1 records · Latest accepted 2023/01/11

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2300078Supplement2023/01/11Wuhan Hai Te Biopharmaceutical Co., Ltd. romanized; Hubei Si Huan Pharmaceutical Co., Ltd. romanizedCDE ↗
盐酸芦氟沙星片 · No verified English name 1 records · Latest accepted 2022/12/29

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2202313Supplement2022/12/29Wuhan Hai Te Biopharmaceutical Co., Ltd. romanized; Hubei Si Huan Pharmaceutical Co., Ltd. romanizedCDE ↗
盐酸芦氟沙星胶囊 · No verified English name 1 records · Latest accepted 2022/12/29

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2202314Supplement2022/12/29Wuhan Hai Te Biopharmaceutical Co., Ltd. romanized; Hubei Si Huan Pharmaceutical Co., Ltd. romanizedCDE ↗
阿奇霉素颗粒 · No verified English name 1 records · Latest accepted 2022/12/29

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2202312Supplement2022/12/29Wuhan Hai Te Biopharmaceutical Co., Ltd. romanized; Hubei Si Huan Pharmaceutical Co., Ltd. romanizedCDE ↗
Roxatidine Acetate Hydrochloride For Injection 1 records · Latest accepted 2022/09/08

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2201488Generic2022/09/08Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗
尼莫地平缓释片 · No verified English name 1 records · Latest accepted 2022/06/17

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2200990Supplement2022/06/17Wuhan Hai Te Biopharmaceutical Co., Ltd. romanized; Hubei Si Huan Pharmaceutical Co., Ltd. romanizedCDE ↗
阿昔洛韦分散片 · No verified English name 1 records · Latest accepted 2022/06/09

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2200919Supplement2022/06/09Wuhan Hai Te Biopharmaceutical Co., Ltd. romanized; Hubei Si Huan Pharmaceutical Co., Ltd. romanizedCDE ↗
Tedizolid Phosphate For Injection 1 records · Latest accepted 2022/01/14

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2200083Generic2022/01/14Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗
注射用重组变构人肿瘤坏死因子相关凋亡诱导配体 · No verified English name 1 records · Latest accepted 2021/12/20

New drug · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CXSS2101065New drug2021/12/20Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗
Parecoxib Sodium for Injection 1 records · Latest accepted 2021/05/17

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2101160Generic2021/05/17Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗

Changes in the last 90 days

0 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.

This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

  1. No matching records were found in the currently loaded source data; coverage dates are listed below.

Under review

2 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Bumetanide Injection CYHB2601065Supplement2026/06/05Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗
Bumetanide Injection CYHS2403001Generic2024/09/11Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗

Catalogue holder records

6 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Isavuconazonium Sulfate for InjectionWuhan Hai Te Biopharmaceutical Co., Ltd. romanizedWuhan Hai Te Biopharmaceutical Co., Ltd. romanized国药准字H202643022026/05/12Generic approved under the new chemical-drug registration classificationCDE ↗
Pentoxifylline InjectionWuhan Hai Te Biopharmaceutical Co., Ltd. romanizedWuhan Hai Te Biopharmaceutical Co., Ltd. romanized国药准字H202491832024/10/29Generic approved under the new chemical-drug registration classificationCDE ↗
Esomeprazole Sodium for InjectionWuhan Hai Te Biopharmaceutical Co., Ltd. romanizedWuhan Hai Te Biopharmaceutical Co., Ltd. romanized国药准字H202446292024/08/05Generic approved under the new chemical-drug registration classificationCDE ↗
Roxatidine Acetate Hydrochloride For InjectionWuhan Hai Te Biopharmaceutical Co., Ltd. romanizedWuhan Hai Te Biopharmaceutical Co., Ltd. romanized国药准字H202438552024/05/28Generic approved under the new chemical-drug registration classificationCDE ↗
Tedizolid Phosphate For InjectionWuhan Hai Te Biopharmaceutical Co., Ltd. romanizedWuhan Hai Te Biopharmaceutical Co., Ltd. romanized国药准字H202341982023/09/28Generic approved under the new chemical-drug registration classificationCDE ↗
Parecoxib Sodium for InjectionWuhan Hai Te Biopharmaceutical Co., Ltd. romanizedWuhan Hai Te Biopharmaceutical Co., Ltd. romanized国药准字H202238412022/11/15Generic approved under the new chemical-drug registration classificationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.

NameCompany / applicantRegistration numberStatusSource update dateView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

6 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Sildenafil Citrate Oral Disintegrating Tablets CYHB2601448Supplement2026/07/28Heng Chang (Guangzhou) Xin Yao Research Co., Ltd. romanized; Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗
Nafamostat Mesilate for Injection CYHS2601711Generic2026/07/17Fujian Da Pu Biopharmaceuticals Co., Ltd. romanized; Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗
Oseltamivir Phosphate For Oral Suspension CYHS2302613Generic2023/09/27Jiangsu Jia You Pharma Group Co., Ltd. romanized; Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗
Sildenafil Citrate Oral Disintegrating Tablets CYHS2302513Generic2023/09/19Heng Chang (Guangzhou) Xin Yao Research Co., Ltd. romanized; Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗
Oseltamivir Phosphate For Oral Suspension CYHS2302257Generic2023/08/24Heng Chang (Guangzhou) Xin Yao Research Co., Ltd. romanized; Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗
Oseltamivir Phosphate For Oral Suspension CYHS2301853Generic2023/07/11Guo Yao Group Zhi Jun (Shenzhen) Pharmaceutical Co., Ltd. romanized; Wuhan Hai Te Biopharmaceutical Co., Ltd. romanizedCDE ↗

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/13 06:42
Chemical-drug catalogue
Last successful update: 2026/11/13 06:39
Full API register
Last successful update: 2026/11/13 06:41
NMPA drug delivery notices
Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete

First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.